艾司西酞普兰治疗轻至中度抑郁症及改善冠状动脉旁路移植术患者生活质量的效果——一项双盲随机临床试验。
The effect of escitalopram in treating mild to moderate depressive disorder and improving the quality of life in patients undergoing coronary artery bypass grafting - a double-blind randomized clinical trial.
作者信息
Baradaran Abdolvahab, Ardakani Mohammad Reza Khodaie, Bateni Fatemeh Sadat, Asadian-Koohestani Fatemeh, Vahedi Mohsen, Aein Afsaneh, Shahmansouri Nazila, Sadighi Gita
机构信息
Cardiovascular Department of Firouzabadi Hospital, Iran University of Medical Sciences, Tehran, Iran.
Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
出版信息
Front Psychiatry. 2024 Jun 28;15:1342754. doi: 10.3389/fpsyt.2024.1342754. eCollection 2024.
INTRODUCTION
Chronic depression and anxiety can be a risk factor for coronary aArtery bypass grafting (CABG) and is an emerging factor after coronary artery disease when the patient is admitted to the hospital and after surgery. We aimed to assess the effect of Escitalopram in treating mild to moderate depressive disorder and improving the quality of life in patients undergoing CABG.
METHODS
In this randomized clinical trial, 50 patients undergoing CABG referred to Tehran Heart Hospital from January 2021 to May 2021 and were suffering from mild to moderate depression were randomly assigned to one of the two groups of Escitalopram or placebo. The level of depression was assessed based on Beck's depression inventory and the quality-of-life status and its domains were assessed based on the SF-36 questionnaire in 2 groups. Measurements were obtained at baseline and at four and eight weeks after treatment. Chi-square, Fisher's exact, paired, and Wilcoxon tests or ANOVA were used as appropriate.
RESULTS
There was no significant difference between the level of depression between the two study groups at baseline (P=0.312). There was no significant difference between the quality of life and its domains in the two study groups at baseline (P=0.607). However, the most important effect of Escitalopram was reducing depression scores in the intervention group at weeks 4 and 8 after treatment compared to the placebo group (P<0.001). The quality of life and its domains were significantly higher in the Escitalopram group eight weeks after treatment (P=0.004). The amount of drug side effects at 2 and 4 weeks after treatment had no significant difference between the groups (P>0.05).
CONCLUSION
Escitalopram was effective in treating mild to moderate depressive disorder and improving quality of life in patients undergoing CABG.
CLINICAL TRIAL REGISTRATION
https://irct.behdasht.gov.ir/, identifier IRCT20140126016374N2.
引言
慢性抑郁和焦虑可能是冠状动脉旁路移植术（CABG）的一个风险因素，并且在冠心病患者入院时及术后是一个新出现的因素。我们旨在评估艾司西酞普兰在治疗接受CABG患者的轻至中度抑郁症及改善生活质量方面的效果。
方法
在这项随机临床试验中，2021年1月至2021年5月转诊至德黑兰心脏医院且患有轻至中度抑郁症的50例接受CABG的患者被随机分配至艾司西酞普兰组或安慰剂组这两组之一。基于贝克抑郁量表评估抑郁水平，基于SF-36问卷评估两组患者的生活质量状况及其领域。在基线以及治疗后4周和8周进行测量。根据情况使用卡方检验、费舍尔精确检验、配对检验、威尔科克森检验或方差分析。
结果
两个研究组在基线时的抑郁水平无显著差异（P = 0.312）。两个研究组在基线时的生活质量及其领域无显著差异（P = 0.607）。然而，与安慰剂组相比，艾司西酞普兰最重要的作用是在治疗后第4周和第8周降低了干预组的抑郁评分（P<0.001）。治疗8周后，艾司西酞普兰组的生活质量及其领域显著更高（P = 0.004）。治疗后2周和4周时两组药物副作用的数量无显著差异（P>0.05）。
结论
艾司西酞普兰在治疗接受CABG患者的轻至中度抑郁症及改善生活质量方面有效。
临床试验注册
Zotero 插件